Tesamorelin Research Guide

Full name: Tesamorelin Acetate (Egrifta)

A synthetic GHRH analog FDA-approved for HIV-associated lipodystrophy. Particularly effective at reducing visceral adipose tissue with emerging cognitive benefits.

How Tesamorelin Works

Binds pituitary GHRH receptors with enhanced affinity via hexenoic acid modification. Effective at mobilizing visceral fat via GH-mediated lipolysis.

Dosing Protocol

• Typical dose: 2 mg
• Frequency: Once daily
• Duration: 12-26 weeks
• Route: Subcutaneous injection

Reported Benefits

• Visceral fat reduction (up to 18%)
• FDA-approved safety
• Improved lipid panels
• Cognitive benefits (emerging)
• No significant IGF-1 overshoot

Potential Side Effects

• Injection site reactions
• Joint pain
• Peripheral edema
• Hyperglycemia
• Pruritus

Research Citations

1. Tesamorelin reduces visceral adiposity in HIV patients (2019) - Reduced visceral adipose tissue by 18% at 26 weeks with lipid improvements.
2. Cognitive effects of tesamorelin in adults at risk for AD (2022) - Improved executive function and verbal memory with preserved hippocampal volume vs placebo.

Related Growth Hormone Compounds

• CJC-1295 - Full Profile
• Ipamorelin - Full Profile
• MK-677 (Ibutamoren) - Full Profile
• Sermorelin - Full Profile
• GHRP-2 - Full Profile
• GHRP-6 - Full Profile

View full Tesamorelin profile with 3D molecule viewer →